Clinical trials: Lung Cancer Small Cell Lung Cancer (SCLC)
Non-small Cell Lung Cancer (NSCLC), Cachexia
A Study to Learn About the Study Medicine Called Ponsegromab in Adults With Lung Cancer-Associated Significant Body Weight Loss
Study to investigate the effect of ponsegromab on skeletal muscle mass and physical function in adult participants with non-small cell lung cancer associated cachexia.
- Trial name
- NCT07663630
- Testing
- ponsegromab
- Where
- 7 sites in United States, China
- Volunteers
- 80 people
- Sponsor
- Pfizer
Non Small Cell Lung Cancer
Adjuvant Melatonin for Prevention of Lung Cancer Recurrence and Mortality
There is evidence to support the use of melatonin, a natural health product, as an additional treatment aid for cancer patients.
- Trial name
- AMPLCaRe (NCT00668707)
- Testing
- melatonin
- Where
- 8 sites in Canada
- Volunteers
- 709 people
- Sponsor
- The Canadian College of Naturopathic Medicine
Non Small Cell Lung Cancer, Brain Metastases
The Role of Brain Radiotherapy in Patients With Asymptomatic Brain Metastasis in the Era of Targeted Therapy for NSCLC
Brain metastasis is the most common neurological complication in tumor patients, and lung cancer is the most common tumor with brain metastasis.
- Trial name
- BRATR (NCT04193007)
- Testing
- molecular targeted therapies, Brain Radiotherapy
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Second Affiliated Hospital of Nanchang University
Breast Cancer, Head and Neck Cancer
Docetaxel in Treating Patients With Solid Tumors and Abnormal Liver Function
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of docetaxel in treating patients with advanced solid…
- Conditions
- Breast Cancer, Head and Neck Cancer, Lung Cancer, Ovarian Cancer
- Trial name
- NCT00002901
- Testing
- docetaxel
- Where
- 3 sites in United States
- Sponsor
- City of Hope Medical Center
Tumor or Lymphoma
A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493 in Adult Participants With Advanced or Refractory Solid Tumors or Lymphoma
The purpose of this study is to evaluate the safety, pharmacokinetics (study of what the body does to a drug), and pharmacodynamics (study of what a drug does to the body) of JNJ-42756493, a pan-fibroblast growth factor receptor…
- Trial name
- NCT01703481
- Testing
- JNJ-42756493: Part 1, JNJ-42756493: Part 2, JNJ-42756493: Part 3
- Where
- 37 sites in United States, France and 1 more
- Volunteers
- 188 people
- Sponsor
- Janssen Research & Development, LLC
Metastatic Non Small Cell Lung Cancer
A Randomised Phase II Trial of Osimertinib With or Without SRS for EGFR Mutated NSCLC With Brain Metastases
20-40% of patients with NSCLC will develop brain metastases at some point during their course of disease. Osimertinib has demonstrated intracranial activity in EFGR mutated NSCLC with leptomeningeal disease in the phase 1 BLOOM…
- Trial name
- OUTRUN (NCT03497767)
- Testing
- Osimertinib, Stereotactic Radiosurgery (SRS)
- Where
- 13 sites in Australia, Singapore
- Volunteers
- 40 people
- Sponsor
- Trans Tasman Radiation Oncology Group
Small Cell Lung Carcinoma (SCLC)
DAREONᵀᴹ-8: A Study to Test How Well Different Doses of BI 764532 in Addition to Standard of Care Are Tolerated by People With Advanced Small Cell Lung Cancer
This study is open to adults with extensive stage small cell lung cancer. The study is in people with advanced cancer that are eligible for standard of care including chemotherapy and anti-PD-L1 (Programmed Cell Death Ligand 1)…
- Trial name
- DAREONᵀᴹ-8 (NCT06077500)
- Testing
- BI 764532, Carboplatin, Etoposide
- Where
- 21 sites in United States, Belgium and 6 more
- Volunteers
- 46 people
- Sponsor
- Boehringer Ingelheim
Advanced Solid Tumors
Study of Continuous OSI-906 Dosing
Multicenter, open-label, phase 1, cohort dose escalation study to determine the Maximum Tolerated Dose (MTD) on both Once Daily (QD) and Twice Daily (BID) schedules.
- Trial name
- NCT00514007
- Testing
- OSI-906
- Where
- 2 sites in United States, United Kingdom
- Volunteers
- 95 people
- Sponsor
- Astellas Pharma Inc
Small-cell Lung Cancer, Extensive-stage Small-cell Lung Cancer
Durvalumab in Combination With Standard Chemotherapy of Patients With Extensive Stage Small Cell Lung Cancer
This is a non-interventional, multicenter, prospective observational study and registry of standard clinical practice in patients with Extensive Stage-Small Cell Lung Cancer (ES-SCLC) receiving 1st line treatment with Durvalumab…
- Trial name
- DRIVE (NCT05761977)
- Where
- Greece
- Volunteers
- 50 people
- Sponsor
- Hellenic Cooperative Oncology Group
Esophageal Cancer, Lung Cancer
PET Scan in Patients With Lung and Esophageal Cancers That May Be Removed by Surgery
RATIONALE: Imaging procedures, such as fludeoxyglucose F 18 positron emission tomography (PET) scans, may improve the ability to detect lung and esophageal cancer or their recurrence.
- Trial name
- NCT00002930
- Testing
- positron emission tomography, fludeoxyglucose F 18
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Lung Cancer, Non-Small Cell
Study of Pazopanib and Paclitaxel in Advanced Non-small Cell Lung Cancer
The Phase I part of the study will identify the doses of pazopanib and paclitaxel that can be administered safely in combination. The Phase II part of the study will not be progressed as documented in Protocol Amendment 01.
- Trial name
- NCT00866528
- Testing
- pazopanib, paclitaxel
- Where
- 4 sites in United States, United Kingdom
- Volunteers
- 30 people
- Sponsor
- GlaxoSmithKline
Lung Cancer
Radiation Therapy to Prevent Brain Metastases in Patients With Previously Treated Extensive-Stage Small Cell Lung Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Radiation therapy to the brain may be effective in preventing brain metastases.
- Trial name
- NCT00016211
- Testing
- radiation therapy
- Where
- 49 sites in Belgium, Cyprus and 10 more
- Volunteers
- 287 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Non-small Cell Lung Cancer
Study of Pemetrexed + Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With Tyrosine Kinase Inhibitor- (TKI)-Resistant Epidermal Growth Factor Receptor- (EGFR)-Mutated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-789/KEYNOTE-789)
The purpose of this study is to evaluate the efficacy and safety of pemetrexed plus platinum chemotherapy (carboplatin or cisplatin) with or without pembrolizumab (MK-3475; KEYTRUDA®) in the treatment of adults with the following…
- Trial name
- NCT03515837
- Testing
- pembrolizumab, pemetrexed, carboplatin
- Where
- 158 sites in United States, Australia and 15 more
- Volunteers
- 492 people
- Sponsor
- Merck Sharp & Dohme LLC
Non Small Cell Lung Cancer
Study for Therapy of Locally Advanced or Metastatic Non Small Cell Lung Cancer (NSCLC) With Cisplatin / Docetaxel or Oxaliplatin / Docetaxel
The study compares two combinations of chemotherapy in patients with advanced or metastatic NSCLC: 50% of the patients are treated with cisplatin and docetaxel, the other 50% with oxaliplatin and docetaxel.
- Trial name
- Taxelox (NCT01222312)
- Testing
- Cisplatin, Oxaliplatin, Docetaxel
- Where
- Germany
- Volunteers
- 88 people
- Sponsor
- Krankenhaus Nordwest
Brain Cancer, Neoplasm Metastasis
Phase I Vorinostat Concurrent With Stereotactic Radiosurgery (SRS) in Brain Metastases From Non-Small Cell Lung Cancer
The purpose of this study is to determine the maximum tolerated dose (MTD) of vorinostat given concurrently with stereotactic radiosurgery (SRS) to treat non-small cell lung cancer (NSCLCA) brain metastases in patient with 1-4…
- Conditions
- Brain Cancer, Neoplasm Metastasis, Lung Cancer, Carcinoma, Non-Small-Cell Lung
- Trial name
- NCT00946673
- Testing
- Vorinostat, Radiation Therapy
- Where
- 2 sites in United States
- Volunteers
- 17 people
- Sponsor
- Stanford University
Non Small Cell Lung Cancer
To Predict Efficacy by Detecting Circulating Endothelial Cell Subsets and Blood Perfusion Parameters Changes in Vivo Tumor in Study of QL1101 and Avastin® in Patients With Non-squamous Non-small Cell Lung Cancer
To reveal changes of peripheral markers and blood perfusion parameters in vivo tumor in the study of QL1101 and Avastin® in patients with Non-squamous Non-small Cell Lung Cancer
- Trial name
- NCT03195569
- Testing
- QL1101, Avastin®, Paclitaxel
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Non-small Cell Lung Cancer
An Open-label, Uncontrolled Study of ONO-4578 and ONO-4538 in Combination With Standard-of-care Docetaxel and Ramucirumab as Second-line Therapy in Patients With Advanced or Recurrent Non-small Cell Lung Cancer
This study is PhaseⅠstudy to evaluate the tolerability and safety of ONO-4578 and ONO-4538 in combination with standard-of-care docetaxel and ramucirumab as second-line therapy in patients with advanced or recurrent NSCLC who…
- Trial name
- NCT06542731
- Testing
- ONO-4578, ONO-4538, Docetaxel
- Where
- 13 sites in Japan
- Volunteers
- 42 people
- Sponsor
- Ono Pharmaceutical Co., Ltd.
Renal Cell Cancer Metastatic, Non-small Cell Lung Cancer Metastatic
Intrapleural Instillation of the Nivolumab in Cancer Patients With Pleural Effusion.
Patients with advanced cancers who have pleural effusion, especially those requiring pleural evacuation, experienced poorer survival when treated with immunotherapy.
- Conditions
- Renal Cell Cancer Metastatic, Non-small Cell Lung Cancer Metastatic, Pleural Effusion, Malignant
- Trial name
- NCT04749602
- Testing
- Nivolumab
- Where
- 5 sites in Russia
- Volunteers
- 26 people
- Sponsor
- Kidney Cancer Research Bureau
Carcinoma, Non-Small-Cell Lung
The 'MADe IT' Clinical Trial: Molecular Analyses Directed Individualized Therapy for Advanced Non-Small Cell Lung Cancer
The standard treatment for non-small cell lung cancer, stage IV or IIIB malignant pleural effusion is chemotherapy. The decision to use a regimen is currently determined by toxicity or by physician's preference.
- Trial name
- NCT00215930
- Testing
- Vinorelbine, Docetaxel, Gemcitabine
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Solid Tumors
A Study to Evaluate the Safety, Tolerability, and Antitumor Activity of INCB001158 Plus Epacadostat, With or Without Pembrolizumab, in Advanced Solid Tumors
The purpose of this study is to assess the safety and antitumor activity of INCB001158 plus epacadostat, with or without pembrolizumab, in participants with advanced or metastatic solid tumors.
- Trial name
- NCT03361228
- Testing
- INCB001158, Epacadostat, Pembrolizumab
- Where
- 2 sites in United States
- Volunteers
- 5 people
- Sponsor
- Incyte Corporation
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.